Sofpironium Targets M3 Receptors In Vitro and Shows Early Clinically Meaningful Improvement in Primary Axillary Hyperhidrosis Symptoms. J of Skin 2025, 9 (6), s717. https://doi.org/10.25251/kvstvq23.